219 related articles for article (PubMed ID: 11782913)
1. Interaction of nonpeptidic delta agonists with P-glycoprotein by in situ mouse brain perfusion: liquid chromatography-mass spectrometry analysis and internal standard strategy.
Dagenais C; Ducharme J; Pollack GM
J Pharm Sci; 2002 Jan; 91(1):244-52. PubMed ID: 11782913
[TBL] [Abstract][Full Text] [Related]
2. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
3. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
Dagenais C; Zong J; Ducharme J; Pollack GM
Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
[TBL] [Abstract][Full Text] [Related]
4. Uptake and efflux of the peptidic delta-opioid receptor agonist.
Dagenais C; Ducharme J; Pollack GM
Neurosci Lett; 2001 Apr; 301(3):155-8. PubMed ID: 11257421
[TBL] [Abstract][Full Text] [Related]
5. Variable modulation of opioid brain uptake by P-glycoprotein in mice.
Dagenais C; Graff CL; Pollack GM
Biochem Pharmacol; 2004 Jan; 67(2):269-76. PubMed ID: 14698039
[TBL] [Abstract][Full Text] [Related]
6. Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of 99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2.
Cattelotte J; Tournier N; Rizzo-Padoin N; Schinkel AH; Scherrmann JM; Cisternino S
J Neurochem; 2009 Feb; 108(3):767-75. PubMed ID: 19067785
[TBL] [Abstract][Full Text] [Related]
7. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
8. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
[TBL] [Abstract][Full Text] [Related]
9. In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
Cisternino S; Rousselle C; Debray M; Scherrmann JM
Pharm Res; 2004 Aug; 21(8):1382-9. PubMed ID: 15359572
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.
Chen C; Hanson E; Watson JW; Lee JS
Drug Metab Dispos; 2003 Mar; 31(3):312-8. PubMed ID: 12584158
[TBL] [Abstract][Full Text] [Related]
11. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
[TBL] [Abstract][Full Text] [Related]
12. A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice.
Mason BL; Pariante CM; Thomas SA
Endocrinology; 2008 Oct; 149(10):5244-53. PubMed ID: 18556350
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
14. The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine.
Zhu HJ; Wang JS; DeVane CL; Williard RL; Donovan JL; Middaugh LD; Gibson BB; Patrick KS; Markowitz JS
Drug Metab Dispos; 2006 Jul; 34(7):1116-21. PubMed ID: 16621932
[TBL] [Abstract][Full Text] [Related]
15. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.
Elkiweri IA; Zhang YL; Christians U; Ng KY; Tissot van Patot MC; Henthorn TK
Anesth Analg; 2009 Jan; 108(1):149-59. PubMed ID: 19095843
[TBL] [Abstract][Full Text] [Related]
16. Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.
Zhou ZW; Chen X; Liang J; Yu XY; Wen JY; Zhou SF
Drug Metab Lett; 2007 Aug; 1(3):205-17. PubMed ID: 19356045
[TBL] [Abstract][Full Text] [Related]
17. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
[TBL] [Abstract][Full Text] [Related]
18. P-Glycoprotein attenuates brain uptake of substrates after nasal instillation.
Graff CL; Pollack GM
Pharm Res; 2003 Aug; 20(8):1225-30. PubMed ID: 12948020
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
20. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
